Skip to main content
Fig. 1 | Molecular Cancer

Fig. 1

From: circRIP2 accelerates bladder cancer progression via miR-1305/Tgf-β2/smad3 pathway

Fig. 1

Higher circRIP2 level in bladder cancer associates with better outcome. Divergent (circRIP2, ) and convergent (RIP2, ) primers were designed; a To detect circRIP2 is circular RNA, agarose gel electrophoresis showed that circRIP2 was amplified by divergent primer in cDNA but not in gDNA. GAPDH was taken as negative control; b RNAse R treatment assay was performed, and only circRIP2 showed strong exonuclease resistance but not the RIP2; c sanger sequence of circRIP2; d qPCR was used to evaluate the expression of circRIP2 in 45 paired bladder cancer tissues; e circRIP2 level among 58 bladder cancer tissues was analyzed by T stages; f circRIP2 level among 58 bladder cancer tissues was analyzed by tumor grade; g circRIP2 level among 58 bladder cancer tissues was analyzed by metastasis; h circRIP2 level among 43 patients in following was analyzed for overall survival.

Back to article page